Biopharma Deal Closures Slow Amid Pricing Uncertainty
Healthcare M&A closure rates fell across the sector in 2026 as valuation gaps and buyer selectivity stalled transactions.
Updated on Nov. 19, 2026 in Healthcare

Biopharma deal closure rates declined across the healthcare sector in 2026, even as corporate deal activity was strong in the first half of the year. A high number of sale processes were aborted, partly due to mismatches between seller value expectations and buyer offers after due diligence.
Why it matters
Uncertainty around the U.S. Most Favored Nation drug pricing policy has affected deal volumes and value, and companies are assessing strategic fit and asset quality more carefully. Licensing deals in Europe decreased markedly as firms became less willing to part with European rights for innovative assets.
Corporate deal activity was strong in the first half of 2026 while private equity activity remained subdued and selective. The source gives no exact closure-rate percentages or aborted-deal counts, leaving the scale of the slowdown unquantified.
The players
Jefferies Global Healthcare Conference
An annual investor conference focused on the healthcare and life sciences sector, where industry deal activity is widely discussed.
The details
Private equity activity in 2026 was subdued and selective, and many sale processes were aborted after due diligence exposed gaps between seller expectations and buyer offers. Deals have also been thwarted by geopolitical uncertainty and buyer selectivity, while the Most Favored Nation policy introduced in the U.S. has added pricing uncertainty to the market.
Timeline
First half of 2026: corporate deal activity remained strong.
16-19 November 2026: Jefferies Global Healthcare Conference held in London.
2026: deal closure rates declined and a high number of processes were aborted.
2027: industry experts hope for more market stability.
Market Landscape
The slowdown tracks the introduction of the U.S. Most Favored Nation drug pricing policy, which has made companies less willing to part with European rights for innovative assets. A mid-sized EU-focused biopharma company will need to either go global or find MFN-proof deal opportunities to compete in 2027.
Companies weighing acquisitions or licensing arrangements face tighter valuations and more cautious buyers, which can affect hiring, investment and product pipelines. Shifts in deal flow may also influence which new treatments reach patients and how quickly they arrive.
The takeaway
Deal makers are prioritizing strategic fit and asset quality over volume, so sellers should align valuation expectations with buyer offers early in the process. Firms with European assets should plan for pricing policy changes rather than assume past deal patterns will hold.
What happens next
Industry observers will watch whether 2027 delivers the greater stability that experts hope for, and whether mid-sized EU-focused biopharma firms can secure MFN-proof deal opportunities.
Further reading
Explore more on Healthcare deal trends and industry shifts.
Source note: This article includes information reported by Pharmaceutical Technology.



